Physician profile
Mark Christopher Campbell
NPI 1306841952
$7,971.52
in general payments reported to CMS, 2019-2025
35 companies · $793 in 2025
The $793 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $843 · 2020: $1,042 · 2021: $1,466 · 2022: $1,345 · 2023: $1,395 · 2024: $1,089 · 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,204 · Education: $72.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,204.12 |
| Education | $72.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $1,135.71 | 2019-2025 | Unithroid |
| Amgen INC. | $1,003.46 | 2019-2025 | Repatha, Repatha, Evenity |
| Sanofi-Aventis U.S. LLC | $937.07 | 2019-2025 | |
| Lilly USA, LLC | $885.97 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Corcept Therapeutics | $605.33 | 2020-2025 | Korlym |
| Dexcom, INC. | $390.37 | 2021-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $320.23 | 2020-2025 | Rybelsus, Ozempic |
| Abbott Laboratories | $282.56 | 2020-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Kyowa Kirin, INC. | $252.59 | 2023-2025 | Crysvita |
| Amarin Pharma, INC. | $219.25 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $187.91 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $185.92 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $179.08 | 2019-2025 | Farxiga |
| Xeris Pharmaceuticals, INC. | $161.74 | 2022-2025 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $140.49 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $138.96 | 2019-2025 | Omnipod |
| Abbvie INC. | $129.61 | 2020-2022 | |
| Cequr Corporation | $117.48 | 2024-2025 | Cequr Simplicity |
| Esperion Therapeutics, INC. | $86.01 | 2020-2021 | |
| Ibsa Pharma INC. | $82.39 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.46 | 2019-2025 | Jardiance |
| Radius Health, INC. | $79.22 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $62.44 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ultragenyx Pharmaceutical INC. | $41.27 | 2022-2023 | Crysvita |
| Shire North American Group INC | $39.21 | 2019 | |
| Novartis Pharmaceuticals Corporation | $33.01 | 2024 | |
| Averitas Pharma INC. | $29.92 | 2025 | Qutenza |
| Ascendis Pharma Endocrinology INC | $26.36 | 2023 | |
| Madrigal Pharmaceuticals | $24.08 | 2025 | Rezdiffra |
| Neurocrine Biosciences, INC. | $21.11 | 2025 | |
| Pfizer INC. | $21.03 | 2024 | |
| Ascensia Diabetes Care US INC. | $20.43 | 2022 | |
| Medtronic, INC. | $20.03 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.98 | 2021 | |
| Recordati_rare_diseases_inc. | $12.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.